Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Body Weight Reduction and Metabolic/Biochemical Parameters in Overweight or Obesity

8 juin 2026 mis à jour par: Medical University of Silesia

The Effect of Body Weight Reduction on Selected Metabolic and Biochemical Parameters in Individuals With Overweight or Obesity

This was a single-center prospective observational cohort study conducted in Poland in the context of routine metabolic outpatient care. The study assessed selected metabolic, biochemical, oxidative-stress, inflammatory, and body-composition parameters in individuals with overweight or obesity undergoing standard lifestyle-based body weight reduction management. Participants with BMI > 25 kg/m² were followed before and after body weight reduction, while individuals with normal body weight served as a comparison group. The weight reduction management included individualized dietary recommendations, physical-activity guidance, health education, regular follow-up visits, fasting blood sampling, and body-composition assessment. The aim of the study was to evaluate whether body weight reduction is associated with changes in metabolic and biochemical parameters, with particular attention to glucose and lipid metabolism, oxidative stress, inflammatory markers, adipokines, cytokines, and body-composition changes.

Aperçu de l'étude

Description détaillée

This was a single-center prospective observational cohort study conducted at the Medical University of Silesia in Katowice, Poland, and in a metabolic outpatient clinic in Miasteczko Śląskie, Poland. The study was designed to evaluate the effect of body weight reduction on selected metabolic, biochemical, oxidative-stress, inflammatory, and body-composition parameters in individuals with overweight or obesity.

The study was conducted in the context of routine metabolic outpatient care. Participants with overweight or obesity received standard lifestyle-based body weight reduction management, including individualized dietary recommendations, physical-activity guidance, health education, and regular follow-up visits. The investigators did not assign participants to an investigational medicinal product, medical device, dietary supplement, surgical procedure, pharmacological intervention, or experimental therapy. The study prospectively observed participants receiving routine lifestyle-based weight reduction management and assessed changes in clinical and laboratory parameters before and after body weight reduction.

The approved study protocol planned the inclusion of individuals with overweight or obesity and a normal-weight comparison group. Participants with BMI > 25 kg/m² were evaluated in relation to body weight reduction, while individuals with normal body weight served as a comparison group for selected baseline analyses. Patients with overweight or obesity were assessed by medical examination, dietary and clinical questionnaires, anthropometric measurements, body-composition analysis, and fasting blood sampling. Body-composition analysis included assessment of body weight, fat mass, fat-free mass, skeletal muscle mass, total body water, visceral fat, and related parameters. Blood samples were collected for biochemical analyses, including markers of glucose metabolism, lipid metabolism, oxidative stress, antioxidant status, inflammatory markers, adipokines, cytokines, chemokines, growth factors, and selected cardiovascular-risk parameters.

Participants with overweight or obesity were followed during standard body weight reduction management until clinically relevant weight reduction or achievement of optimal body weight. According to the original study documentation, assessments were planned before the start of weight reduction, after approximately 10% body weight reduction, and after approximately 20% body weight reduction or achievement of target body weight. Follow-up visits included body weight measurements, waist and hip circumference measurements, dietary counselling, education regarding caloric intake, and motivation to continue lifestyle modification.

The primary objective of the study was to assess whether body weight reduction in individuals with overweight or obesity is associated with changes in selected metabolic and biochemical parameters. Secondary objectives included evaluation of oxidative-stress and antioxidant-status parameters, glucose and lipid metabolism, inflammatory markers, adipokines, cytokines, and body-composition changes. The study also aimed to assess relationships between biochemical parameters and body-composition indices before and after body weight reduction.

The study was approved by the Bioethics Committee of the Medical University of Silesia in Katowice, Poland. All participants received information about the study and provided written informed consent before participation. This ClinicalTrials.gov record is submitted retrospectively to meet journal publication requirements and to provide transparent public information about the completed study.

Type d'étude

Observationnel

Inscription (Réel)

53

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Silesian Voivodeship
      • Miasteczko Śląskie, Silesian Voivodeship, Pologne, 42-610
        • Eko-Prof-Med Medical Center, Metabolic Outpatient Clinic
      • Zabrze, Silesian Voivodeship, Pologne, 41-808
        • Department of Biochemistry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Adults with overweight or obesity who received routine lifestyle-based body weight reduction management in a metabolic outpatient clinic in Miasteczko Śląskie, Poland, and who provided written informed consent for participation in the study.

La description

Inclusion Criteria:

  • Adults aged 18-85 years
  • BMI > 25 kg/m²
  • Overweight or obesity diagnosed on the basis of medical examination and body-composition assessment
  • Participation in routine lifestyle-based body weight reduction management in a metabolic outpatient clinic
  • Written informed consent to participate in the study

Exclusion Criteria:

  • Lack of informed consent
  • Severe hepatic insufficiency
  • Severe renal insufficiency
  • Severe respiratory insufficiency
  • Severe circulatory insufficiency
  • Disturbances of consciousness
  • Treatment-resistant depression
  • Chronic alcohol abuse
  • Pregnancy
  • History of serious nervous system injury
  • Implanted cardiac pacemaker
  • Pharmacological treatment affecting glucose and/or lipid metabolism
  • Incomplete follow-up or incomplete laboratory data

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Individuals With Overweight or Obesity
Adults with BMI > 25 kg/m² who were receiving routine lifestyle-based body weight reduction management in a metabolic outpatient clinic. Participants were prospectively observed and assessed before and after body weight reduction. Assessments included clinical and dietary questionnaires, anthropometric measurements, body-composition analysis, fasting blood sampling, and biochemical, metabolic, oxidative-stress, inflammatory, adipokine, and cytokine measurements.
Standard lifestyle-based body weight reduction management received as part of routine metabolic outpatient care. It included individualized dietary recommendations, physical-activity guidance, health education, and regular follow-up visits. Participants were not assigned to this management as part of the study; the study prospectively observed patients receiving routine care and assessed metabolic, biochemical, inflammatory, oxidative-stress, adipokine, cytokine, and body-composition parameters before and after body weight reduction.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in Body Weight
Délai: Baseline and after body weight reduction, up to approximately 6 months
Change in body weight from baseline to follow-up after routine lifestyle-based body weight reduction management.
Baseline and after body weight reduction, up to approximately 6 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in Body Fat Mass
Délai: Baseline and after body weight reduction, up to approximately 6 months
Change in body fat mass assessed by bioelectrical impedance analysis and expressed in kilograms.
Baseline and after body weight reduction, up to approximately 6 months
Change in Glucose concentration in mg/dl.
Délai: Baseline and after body weight reduction, up to approximately 6 months
Changes in fasting glucose.
Baseline and after body weight reduction, up to approximately 6 months
Change in total-cholesterol concentration in mg/dl.
Délai: Baseline and after body weight reduction, up to approximately 6 months
Changes in total cholesterol concentration.
Baseline and after body weight reduction, up to approximately 6 months
Change in malondialdehyde concentration in μmol/l.
Délai: Baseline and after body weight reduction, up to approximately 6 months
Change in blood malondialdehyde concentration, assessed as a marker of lipid peroxidation and oxidative stress, from baseline to follow-up after body weight reduction.
Baseline and after body weight reduction, up to approximately 6 months
Change in serum IL-6 concentration in pg/ml.
Délai: Baseline and after body weight reduction, up to approximately 6 months
Change in serum interleukin-6 (IL-6) concentration from baseline to follow-up after body weight reduction. IL-6 was measured in serum samples as a marker of systemic low-grade inflammation and expressed in pg/ml.
Baseline and after body weight reduction, up to approximately 6 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Sławomir Kasperczyk, Prof, Medical University of Silesia in Katowice

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

10 mai 2016

Achèvement primaire (Réel)

30 septembre 2022

Achèvement de l'étude (Réel)

30 septembre 2022

Dates d'inscription aux études

Première soumission

2 juin 2026

Première soumission répondant aux critères de contrôle qualité

8 juin 2026

Première publication (Réel)

12 juin 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 juin 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

8 juin 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • KNW/0022/KB1/19/I/16
  • Secondary ID: KNW-1-016/N/7/2 (Autre subvention/numéro de financement: Medical University of Silesia)
  • Secondary ID: KNW-1/109/K/8/Z (Autre identifiant: Medical University of Silesia)
  • Secondary ID: KNW-1/171/K/9/O (Autre identifiant: Medical University of Silesia)
  • Secondary ID: PCN-1-049/K/0/O (Autre identifiant: Medical University of Silesia)
  • Secondary ID: PCN-1-018/K/1/O (Autre identifiant: Medical University of Silesia)
  • Secondary ID: PCN-1-132/K/2/O (Autre identifiant: Medical University of Silesia)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Individual participant data will not be made publicly available because of privacy and confidentiality restrictions, limitations of the original informed consent, and the retrospective registration of this completed study. De-identified aggregate data or non-identifiable datasets may be made available from the investigators upon reasonable request, subject to institutional approval and applicable data protection regulations.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner